$ACTG

OCONNELL MAUREEN sold $46K of ACTG

OCONNELL MAUREEN sold 10,000 shares of ACACIA RESEARCH CORP (ACTG) at $4.60 on 2026-08-19.

Original reporting
SEC EDGAR · OCONNELL MAUREEN
Published Aug 20, 2026, 11:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 11:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ACTG
Neutral
high confidence
Mentioned
$ACTG
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACTGNeutralLow
01

Why it matters

The director's sale is modest and does not suggest a change in outlook for the company.

02

Market read

Limited relevance; typical insider sale with minimal market impact.

03

What to watch

Potential upcoming corporate actions or market conditions not disclosed in the filing.

Relevance 3/10Novelty 4/10Timing: post-market 2026-08-20

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$ACTGNeutralHigh confidence
Context

Director Maureen O'Connell sold 10,000 shares for $46,000, reducing her stake to 287,655 shares.

Expected impact

No material price impact expected.

Evidence & confidence

The transaction size is small relative to float and typical insider sales of this magnitude rarely affect price.

Market effects

None; the sale does not affect the broader sector.

None; limited to the individual stock.

None

Counterpoint

The sale could be interpreted as a lack of confidence, but size is too small to be meaningful.

Key entities

  • Acacia Research Corp

    US-listed biotech firm (NASDAQ: ACTG).

  • Maureen O'Connell

    Director of Acacia Research Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACTGMedAI 8/10

Acacia Research (ACTG) Q2 2026 Earnings Call Transcript

Acacia Research (ACTG) reported Q2 2026 revenue of $114.6 million, up from $51.2 million a year earlier, mainly from a $60.9 million IP licensing settlement with TP-Link. Adjusted diluted EPS was $0.13. GAAP net income was $47,000, including a $30.9 million noncash impairment tied to Life Sciences holdings. Cash and liquidity were $334.6 million.